Jay Luly, Enanta Pharmaceuticals CEO
April 25, 2023 02:27 PM EDTUpdated April 26, 10:30 AM
Deals
Pharma

Enan­ta sells off over 50% of roy­al­ty pay­ments from Mavyret in ex­change for $200M

Katherine Lewin

News Reporter

Enan­ta Phar­ma­ceu­ti­cals is sell­ing off roy­al­ty pay­ments from its Ab­b­Vie-part­nered drug Mavyret, its biggest rev­enue dri­ver, to a Cana­di­an pen­sion plan …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

A service from the Financial Times